Small molecule activators of nrf2 pathway
AssigneeThe Regents of the University of California
InventorsAleksey G. Kazantsev, Leslie M. Thompson, Ruben Abagyan, Malcolm Casale
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
Claims21
A method for treating a neurodegenerative disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
(canceled) .
A method for treating an inflammatory disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
(canceled) .
(canceled) .
A method for promoting survival of a eukaryotic cell, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
-19. (canceled)
A method for treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
-32. (canceled)
Dependencies are inferred from the claim text.